Kongsberg Gruppen ASA (OSL:KOG)

Revance Therapeutics Revenue

Kongsberg Gruppen ASA had revenue of 13.74B NOK in the quarter ending June 30, 2025, with 18.57% growth. This brings the company's revenue in the last twelve months to 53.15B, up 18.23% year-over-year. In the year 2024, Kongsberg Gruppen ASA had annual revenue of 48.87B with 20.32% growth.

• Revenue (ttm): 53.15B
• Revenue Growth: +18.23%
• P/S Ratio: 5.04
• Revenue / Employee: 3.54M
• Employees: 14,629
• Market Cap: 267.83B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	48.87B	8.26B	20.32%
Dec 31, 2023	40.62B	8.81B	27.71%
Dec 31, 2022	31.80B	4.35B	15.86%
Dec 31, 2021	27.45B	1.84B	7.17%
Dec 31, 2020	25.61B	2.37B	10.18%